RP
RPID.O
—
NASDAQ
Advanced Medical Equipment & Technology
Rapid Micro Biosystems, Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
97,0M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-141,1 %
ROE
-141,9 %
Net margin
-140,3 %
Debt / equity
0,57
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$2,09
Open
$2,26
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Rapid Micro Biosystems, Inc is a developer and manufacturer of rapid microbial detection and identification systems for use in clinical and industrial microbiology laboratories.
Business. Rapid Micro Biosystems, Inc. (RPID.O) is a healthcare services and equipment company operating in the advanced medical equipment and technology industry. The firm primarily engages in the sale of products within this sector. Headquarters and specific operating segment details are not provided in the available data. The company is listed on the NASDAQ stock exchange.
Classification99 %
SectorHealth Care
Industry groupAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
BUY4 analysts
4 buy0 hold0 sell
Avg 12m price target6,67
Analyst recommendations
4 analysts · consensus BuyBuy4
Hold0
Sell0
12-month price target
6,67
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
4 analysts · indicative
Ownership→
Dimensional Fund Advisors, L.P.
largest disclosed fund holder
Profitability→
-141,9 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,7 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Consumer Discretionary+0,4 %+7,7 %−0,2 %
Information Technology+0,3 %+7,8 %−0,3 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to RPID.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Rapid Micro Biosystems, Inc. (RPID.O) is a healthcare services and equipment company operating in the advanced medical equipment and technology industry. The firm primarily engages in the sale of products within this sector. Headquarters and specific operating segment details are not provided in the available data. The company is listed on the NASDAQ stock exchange.
Classification99 %
SectorHealth Care
Industry groupAdvanced Medical Equipment & Technology
AI synthesis
GENERATEDRapid Micro Biosystems has a market capitalization of $117.16 million and a price-to-book ratio of 3.53, indicating that the market is valuing the company at a premium to its book value. The company's liquidity position is characterized by $20.03 million in cash and equivalents, which is a significant portion of its total assets of $74.85 million. However, the company reported negative operating and net income of $47.39 million and $47.12 million, respectively, in the latest period.
The company's profitability is underperforming relative to industry standards, as evidenced by a return on equity of -141.91% and a return on assets of -62.95%. These figures suggest that the company is not generating returns that meet the cost of capital for either equity or total assets. The gross profit of $1.05 million is significantly lower than the company's operating expenses, contributing to the net loss.
Geographically and segment-wise, the company's exposure is not disclosed in the available data. However, the company's revenue of $33.59 million is concentrated in a single business line, which could pose a concentration risk if demand for its products declines or if the company fails to expand into new markets.
The company's growth trajectory is currently negative, with a significant operating loss and negative cash flows from operations of $31.06 million. The capital expenditure of $850,000 indicates that the company is investing in its operations, but the negative free cash flow of $44.72 million suggests that the company is not generating enough cash to sustain operations without external financing.
The risk assessment indicates a low level of liquidity risk, but the company's debt-to-equity ratio of 0.57 suggests that it is not overly leveraged. The risk of dilution is also assessed as low, with no immediate filing-based liquidity or dilution flags detected. The company's capital structure is supported by $19.09 million in long-term debt and $41.65 million in total liabilities, which is offset by $33.21 million in total equity.
Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's stock is currently trading at $2.56, and analyst estimates suggest a mean price target of $8.00, indicating a potential upside of 212% from the current price. The mean recommendation of 1.75 suggests a generally positive outlook from analysts, with one strong-buy and three buy ratings.
Key takeaways
- Rapid Micro Biosystems is trading at a price-to-book ratio of 3.53, indicating a premium to its book value.
- The company reported a significant net loss of $47.12 million, with a return on equity of -141.91%.
- The company's liquidity position is supported by $20.03 million in cash and equivalents.
- Analysts have a generally positive outlook, with a mean price target of $8.00 and a mean recommendation of 1.75.
- The company's growth trajectory is currently negative, with a significant operating loss and negative cash flows from operations.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$2,12
Market cap
$117.2M
Enterprise valueⓘ
$116.2M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
3.5x
P / Tangible bookⓘ
3.5x
Tangible book
$33.2M
Net cashⓘ
$941.0k
Current ratioⓘ
3.3
Debt / equityⓘ
0.6
ROAⓘ
-62.9%
ROEⓘ
-1.4%
Cash conversionⓘ
66.0%
CapEx / revenueⓘ
-2.5%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships4 disclosed relationships · 1 type · extracted from filings & disclosures
Subsidiaries4
EX21:2525314145e4EX21:2525314145e4Subsidiarie97%
EX21:2ebc78daaf51EX21:2ebc78daaf51Subsidiarie97%
EX21:357d45fca9caEX21:357d45fca9caSubsidiarie97%
EX21:ca5d3fce5592EX21:ca5d3fce5592Subsidiarie97%
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs RPID · multiples and returns
TM
TMO—
Thermo Fisher Scientific Inc
$574,03
214,1B USDP/E
29,4x
— vs self
Div yield
0,3 %
— vs self
ROE
12,9 %
+243,9 vs self
DH
DHR—
Danaher Corp
$201,85
143,2B USDP/E
38,2x
— vs self
Div yield
—
— vs self
ROE
6,9 %
+237,9 vs self
GE
GEHC—
GE HEALTHCARE TECHNOLOGIES INC.
$69,91
31,9B USDP/E
13,6x
— vs self
Div yield
0,2 %
— vs self
ROE
19,5 %
+250,6 vs self
PH
PHG—
PHG
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BS
BSX—
Boston Scientific Corp
$48,70
72,8B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
IS
ISRG—
INTUITIVE SURGICAL, INC.
$375,12
132,9B USDP/E
287,7x
— vs self
Div yield
—
— vs self
ROE
3,6 %
+234,6 vs self
A
A—
Agilent Technologies Inc
$139,80
39,6B USDP/E
29,0x
— vs self
Div yield
0,8 %
— vs self
ROE
19,3 %
+250,3 vs self
EW
EW—
Edwards Lifesciences Corp
$86,78
50,4B USDP/E
44,3x
— vs self
Div yield
—
— vs self
ROE
10,4 %
+241,4 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,93
Predicted surprise
-0,07
Beat probability
45 %
Analysts
4
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
revision ratio -0,01 · as of 2026-07-17 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,93 |
| Revenue | —no estimate | —no estimate | 39,1M USD |
| Operating income | —no estimate | —no estimate | -44,2M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution4 analysts
Strong buy1
Buy3
Hold0
Sell0
Strong sell0
12-month price target$6,67 · Median $7,00
Low $5,00High $8,00
Operating income · consensus-44,2M USD
EPS surprise
−12,9 %
reported vs consensus · miss
Revenue surprise
−14,2 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$5,00
Mean$6,67
Median$7,00
High$8,00
Spot$2,12
+214.5 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-141,1 %Below median
Net Margin-140,3 %Below median
ROE-141,9 %Bottom quartile
Capex / Rev-2,5 %Above median
D/E0,57Bottom quartile
Cash Conv0,66Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 5 577 528 sh1 exercises · 18 grants10 insiders
- Director · Series B Warrant (right to buy) → Class A Common StockAcquired 12 787 @ $2,34grant · 2026-05-29
- Director · Series A Warrant (right to buy) → Class A Common StockAcquired 12 787 @ $1,96grant · 2026-05-29
- Director · Series B Warrant (right to buy) → Class A Common StockAcquired 12 787 @ $2,34grant · 2026-05-29
- Director · Series A Warrant (right to buy) → Class A Common StockAcquired 12 787 @ $1,96grant · 2026-05-29
- Director · Series B Warrant (right to buy) → Class A Common StockAcquired 12 787 @ $2,34grant · 2026-05-29
- Director · Series A Warrant (right to buy) → Class A Common StockAcquired 12 787 @ $1,96grant · 2026-05-29
- CHIEF FINANCIAL OFFICER · Series A Warrant (right to buy) → Class A Common StockAcquired 12 787 @ $1,96grant · 2026-05-29
- CHIEF FINANCIAL OFFICER · Series B Warrant (right to buy) → Class A Common StockAcquired 12 787 @ $2,34grant · 2026-05-29
- Director, PRESIDENT AND CEO · Series A Warrant (right to buy) → Class A Common StockAcquired 12 787 @ $1,96grant · 2026-05-29
- Director, PRESIDENT AND CEO · Series B Warrant (right to buy) → Class A Common StockAcquired 12 787 @ $2,34grant · 2026-05-29
- Director · Stock Option (Right to Buy) → Class A Common StockAcquired 38 700 @ $2,07grant · 2026-05-21
- Director · Stock Option (Right to Buy) → Class A Common StockAcquired 38 700 @ $2,07grant · 2026-05-21
- Director · Stock Option (Right to Buy) → Class A Common StockAcquired 38 700 @ $2,07grant · 2026-05-21
- Director · Stock Option (Right to Buy) → Class A Common StockAcquired 38 700 @ $2,07grant · 2026-05-21
- Director · Stock Option (Right to Buy) → Class A Common StockAcquired 38 700 @ $2,07grant · 2026-05-21
- 10% owner · Pre-Funded Warrant (right to buy) → Class A Common StockAcquired 1 463 000 @ $0,01purchase · 2026-05-20
- 10% owner · Series B Warrant (right to buy) → Class A Common StockAcquired 1 463 000 @ $2,34purchase · 2026-05-20
- 10% owner · Series A Warrant (right to buy) → Class A Common StockAcquired 1 463 000 @ $1,96purchase · 2026-05-20
- Director · Stock Option (Right to Buy) → Class A Common StockDisposed 842 @ $0,75exercise · 2026-02-27
- CHIEF FINANCIAL OFFICER · Stock Option (Right to Buy) → Class A Common StockAcquired 193 000 @ $4,20grant · 2026-02-11
- Director, PRESIDENT AND CEO · Stock Option (Right to Buy) → Class A Common StockAcquired 528 000 @ $4,20grant · 2026-02-11
- CHIEF OPERATING OFFICER · Stock Option (Right to Buy) → Class A Common StockAcquired 147 000 @ $4,20grant · 2026-02-11
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
Source documents
- Rapid Micro Biosystems, Inc Market data — financials · 2026-05-29
- Rapid Micro Biosystems, Inc Market data — analyst estimates · 2026-05-29
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Net selling0 buys · 10 sellsnet -$664K10 insiders · last 365d
- Director · Class A Common StockOther 12 787 @ $1,96$25K · 2026-05-29
- Director · Class A Common StockOther 12 787 @ $1,96$25K · 2026-05-29
- Director · Class A Common StockOther 12 787 @ $1,96$25K · 2026-05-29
- CHIEF FINANCIAL OFFICER · Class A Common StockOther 12 787 @ $1,96$25K · 2026-05-29
- Director, PRESIDENT AND CEO · Class A Common StockOther 12 787 @ $1,96$25K · 2026-05-29
- Director · Class A Common StockOther 19 300 · 2026-05-21
- Director · Class A Common StockOther 19 300 · 2026-05-21
- Director · Class A Common StockOther 19 300 · 2026-05-21
- Director · Class A Common StockOther 19 300 · 2026-05-21
- Director · Class A Common StockOther 19 300 · 2026-05-21
- CHIEF OPERATING OFFICER · Class A Common StockSold 9 603 @ $4,32$41K · 2026-03-11
- CHIEF FINANCIAL OFFICER · Class A Common StockSold 7 480 @ $4,32$32K · 2026-03-11
- Director, PRESIDENT AND CEO · Class A Common StockSold 17 922 @ $4,11$74K · 2026-03-10
- Director · Class A Common StockOther 842 @ $0,75$632 · 2026-02-27
- CHIEF OPERATING OFFICER · Class A Common StockSold 5 403 @ $3,92$21K · 2026-02-20
- CHIEF FINANCIAL OFFICER · Class A Common StockSold 17 254 @ $3,92$68K · 2026-02-20
- Director, PRESIDENT AND CEO · Class A Common StockSold 38 327 @ $3,89$149K · 2026-02-19
- CHIEF OPERATING OFFICER · Class A Common StockOther 74 000 · 2026-02-11
- CHIEF FINANCIAL OFFICER · Class A Common StockOther 97 000 · 2026-02-11
- Director, PRESIDENT AND CEO · Class A Common StockOther 264 000 · 2026-02-11
- CHIEF OPERATING OFFICER · Class A Common StockSold 4 610 @ $3,78$17K · 2026-02-09
- CHIEF FINANCIAL OFFICER · Class A Common StockSold 6 027 @ $3,78$23K · 2026-02-09
- Director, PRESIDENT AND CEO · Class A Common StockSold 12 840 @ $3,78$49K · 2026-02-09
- 10% owner · Class A Common StockSold 49 000 @ $3,88$190K · 2026-02-04
Short positioning
842.3Kshares short+14.1% vs prior
3.19days to cover
79.4%short of daily vol
3.8Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
RPID.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorSubsidiaries
Evidence & claims
From filings & derived data- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 2.8%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 18.4%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 19.7%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 2.8%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -6.8%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 82.5%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -0.5%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -23.8%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -55.9%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 29.6%Derived (calculated)
- Net margin (FY 2025-12-31): -140.3%Derived (calculated)
- Return on equity (FY 2025-12-31): -141.9%Derived (calculated)
- Return on assets (FY 2025-12-31): -63.0%Derived (calculated)
- Current ratio (FY 2025-12-31): 3.31xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.25xDerived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 5.1%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -37.7%Derived (calculated)
- Capex (annual): USD 850KSEC XBRL filing
- Shareholders' equity (annual): USD 33.21MSEC XBRL filing
- Cash & equivalents (annual): USD 20.03MSEC XBRL filing
- Net income (annual): USD -47.12MSEC XBRL filing
- R&D expense (annual): USD 13.6MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
- Operating income (annual): USD -47.39MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-12 21:55 UTCEVENTHa Price Move RPID extraordinary up move (20.594% 1d, 4.01x sigma) on x4.19 volume
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-05-29 00:00 UTCINSIDER28 insider transactions — 2026-05 · net buy $125k 18 derivative
2026-05-29INSIDERLOWENSTEIN INESE transacted 12.8k sh Class A Common Stock — Director ~$25k
2026-05-29INSIDERPEI MELINDA LITHERLAND transacted 12.8k sh Class A Common Stock — Director ~$25k
2026-05-29INSIDERMalloy Kirk transacted 12.8k sh Class A Common Stock — Director ~$25k
2026-05-29INSIDERWIRTJES SEAN M transacted 12.8k sh Class A Common Stock — CHIEF FINANCIAL OFFICER ~$25k
2026-05-29INSIDERSpignesi Robert G. Jr. transacted 12.8k sh Class A Common Stock — Director, PRESIDENT AND CEO ~$25k
2026-05-29INSIDERMalloy Kirk acquired 12.8k sh Series B Warrant (right to buy) — Director
2026-05-29INSIDERLOWENSTEIN INESE acquired 12.8k sh Series A Warrant (right to buy) — Director
2026-05-29INSIDERPEI MELINDA LITHERLAND acquired 12.8k sh Series A Warrant (right to buy) — Director
2026-05-29INSIDERWIRTJES SEAN M acquired 12.8k sh Series A Warrant (right to buy) — CHIEF FINANCIAL OFFICER
2026-05-29INSIDERSpignesi Robert G. Jr. acquired 12.8k sh Series A Warrant (right to buy) — Director, PRESIDENT AND CEO
2026-05-21INSIDERMalloy Kirk transacted 19.3k sh Class A Common Stock — Director
2026-05-21INSIDERLOWENSTEIN INESE transacted 19.3k sh Class A Common Stock — Director
2026-05-21INSIDERPEI MELINDA LITHERLAND transacted 19.3k sh Class A Common Stock — Director
2026-05-21INSIDERKollender Richard S transacted 19.3k sh Class A Common Stock — Director
2026-05-21INSIDERBika Dafni transacted 19.3k sh Class A Common Stock — Director
2026-05-21INSIDERMalloy Kirk acquired 38.7k sh Stock Option (Right to Buy) — Director
2026-05-21INSIDERLOWENSTEIN INESE acquired 38.7k sh Stock Option (Right to Buy) — Director
2026-05-21INSIDERBika Dafni acquired 38.7k sh Stock Option (Right to Buy) — Director
2026-05-21INSIDERKollender Richard S acquired 38.7k sh Stock Option (Right to Buy) — Director
2026-05-21INSIDERPEI MELINDA LITHERLAND acquired 38.7k sh Stock Option (Right to Buy) — Director
2026-05-20INSIDERBain Capital Life Sciences Investors, LLC acquired 1.46M sh Pre-Funded Warrant (right to buy) — 10% owner
2026-03-11 00:00 UTCINSIDER3 insider transactions — 2026-03 · net sell $147k
2026-03-11INSIDERWilson John J. Addington sold 9.6k sh Class A Common Stock — CHIEF OPERATING OFFICER ~$41k
2026-03-11INSIDERWIRTJES SEAN M sold 7.5k sh Class A Common Stock — CHIEF FINANCIAL OFFICER ~$32k
2026-03-10INSIDERSpignesi Robert G. Jr. sold 17.9k sh Class A Common Stock — Director, PRESIDENT AND CEO ~$74k
2026-02-27 00:00 UTCINSIDER15 insider transactions — 2026-02 · net sell $516k 4 derivative
Showing the 40 most recent of 51 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage